reports
- Nitin Agarwal
NATCO Pharma's Q2FY19 results (Outperformer) - Good quarter; announces...
Q2FY19 result highlights Natco reported higher sales of Rs5.4b (+27% yoy) vs est of Rs5.1b. The surprise was driven by higher other operating income – Rs540m Formulation exports came in line at Rs2.48bn (Rs2.36bn in Q1) driven by profit share on key drugs including gTamiflu, gCopaxone etc. Domestic biz continues to inch by steadily with continued momentum in oncology sales and stabilization in Hep-C sales. Natco reported higher EBITDA of Rs2.2bn (+81% yoy) vs our est of Rs1.9bn. EBITDA marg...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.